This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

OvaScience And Intrexon Collaborate To Accelerate Development Of OvaScience’s OvaTure℠ Technology For Infertility Treatments

OvaScience, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, and Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced an agreement to access Intrexon’s portfolio of technologies to accelerate the development of OvaScience’s OvaTure technology platform. Separately, the companies established a Joint Venture, called OvaXon, to combine their unique technology platforms to create new applications for improving human and animal health.

“We are accelerating the development for OvaTure by applying Intrexon’s industrialized synthetic biology platform to enhance our process for the maturation of egg precursor cells (EggPCs) into high quality eggs,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “This is a major step toward our goal of bringing new treatments to women seeking further options for infertility. At the same time, the joint venture with Intrexon will allow us to broaden the potential of our EggPC platform to develop therapeutics for the prevention of inherited diseases in future generations.”

OvaTure is OvaScience’s next-generation approach to in vitro fertilization (IVF) using a woman’s own EggPCs, which are immature egg cells found in the outer edge of the ovaries. OvaScience uses proprietary methods to identify, isolate and mature EggPCs into high quality eggs for in vitro fertilization without the need for hormone injections. Importantly, OvaTure may provide a new treatment option for women with compromised eggs, or who may be unwilling or unable to undergo hormone hyperstimulation, such as women diagnosed with cancer who seek to preserve their future fertility.

Through the Exclusive Channel Collaboration (ECC) between the companies, Intrexon will use its proprietary Cell Systems Informatics, UltraVector ®, RheoSwitch ®, AttSite ®, and LEAP™ technologies, to develop methodologies to enable the accelerated and scalable development of OvaTure. In addition and as part of the Joint Venture, the combination of OvaScience’s EggPC platform with Intrexon’s genome engineering capabilities offers an innovative approach to the prevention of inherited diseases in humans, such as mitochondrial and other genetic disorders.

Samuel Broder, M.D., Senior Vice President of Intrexon’s Health Sector and former Director of the National Cancer Institute, underscored the potential for this collaboration.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs